190 related articles for article (PubMed ID: 11927281)
21. Letrozole in breast cancer.
Shahab N
N Engl J Med; 2004 Feb; 350(7):727-30; author reply 727-30. PubMed ID: 14971058
[No Abstract] [Full Text] [Related]
22. Anastrozole: a new addition to the armamentarium against advanced breast cancer.
Buzdar AU
Am J Clin Oncol; 1998 Apr; 21(2):161-6. PubMed ID: 9537204
[TBL] [Abstract][Full Text] [Related]
23. Anastrozole (Arimidex)--an aromatase inhibitor for the adjuvant setting?
Buzdar AU
Br J Cancer; 2001 Nov; 85 Suppl 2(Suppl 2):6-10. PubMed ID: 11900212
[TBL] [Abstract][Full Text] [Related]
24. A better medication for treating breast cancer?
Johns Hopkins Med Lett Health After 50; 2002 May; 14(3):3. PubMed ID: 12004835
[No Abstract] [Full Text] [Related]
25. The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.
Morandi P; Rouzier R; Altundag K; Buzdar AU; Theriault RL; Hortobagyi G
Cancer; 2004 Oct; 101(7):1482-9. PubMed ID: 15378476
[TBL] [Abstract][Full Text] [Related]
26. Anastrozole: in early breast cancer.
Wellington K; Faulds DM
Drugs; 2002; 62(17):2483-90; discussion 2491-2. PubMed ID: 12421108
[TBL] [Abstract][Full Text] [Related]
27. Use of aromatase inhibitors in postmenopausal women with advanced breast cancer.
Roseman BJ; Buzdar AU; Singletary SE
J Surg Oncol; 1997 Nov; 66(3):215-20. PubMed ID: 9369969
[TBL] [Abstract][Full Text] [Related]
28. Anastrozole (Arimidex), a new aromatase inhibitor for advanced breast cancer: mechanism of action and role in management.
Hortobagyi GN; Buzdar AU
Cancer Invest; 1998; 16(6):385-90. PubMed ID: 9679529
[No Abstract] [Full Text] [Related]
29. Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: emerging data.
Buzdar AU; Cuzick J
Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1037s-1048s. PubMed ID: 16467122
[TBL] [Abstract][Full Text] [Related]
30. Adjuvant aromatase inhibitor therapy for early breast cancer: A review of the most recent data.
Grana G
J Surg Oncol; 2006 Jun; 93(7):585-92. PubMed ID: 16705732
[TBL] [Abstract][Full Text] [Related]
31. Aromatase inhibitors and their future role in post-menopausal women with early breast cancer.
Lønning PE
Br J Cancer; 1998 Sep; 78 Suppl 4(Suppl 4):12-5. PubMed ID: 9741783
[TBL] [Abstract][Full Text] [Related]
32. The adjuvant endocrine treatment revolution: focus on anastrozole.
Jakesz R
Expert Opin Drug Metab Toxicol; 2006 Apr; 2(2):301-12. PubMed ID: 16866615
[TBL] [Abstract][Full Text] [Related]
33. Changes in endocrine therapy: anastrozole and advanced breast cancer in postmenopausal women.
Nabholtz JM
Am J Hosp Palliat Care; 2004; 21(6):457-65. PubMed ID: 15612238
[TBL] [Abstract][Full Text] [Related]
34. [Campaign against breast cancer. Are aromatase inhibitors the better choice? (interview by Dr. Dorothea Dlugosch)].
Bruntsch U
MMW Fortschr Med; 2002 Sep; 144(38):20. PubMed ID: 12395697
[No Abstract] [Full Text] [Related]
35. Aromatase inhibitors in the adjuvant setting: bringing the gold to a standard?
Clemons M; Coleman RE; Verma S
Cancer Treat Rev; 2004 Jun; 30(4):325-32. PubMed ID: 15145507
[TBL] [Abstract][Full Text] [Related]
36. Breast cancer studies challenge tamoxifen therapy.
Timms B
Lancet Oncol; 2000 Nov; 1():132. PubMed ID: 11905647
[No Abstract] [Full Text] [Related]
37. New treatment option for postmenopausal women with early breast cancer.
Expert Rev Anticancer Ther; 2002 Dec; 2(6):617. PubMed ID: 12503198
[No Abstract] [Full Text] [Related]
38. Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: a prospective, randomized, phase III study.
Milla-Santos A; Milla L; Portella J; Rallo L; Pons M; Rodes E; Casanovas J; Puig-Gali M
Am J Clin Oncol; 2003 Jun; 26(3):317-22. PubMed ID: 12796608
[TBL] [Abstract][Full Text] [Related]
39. Anastrozole.
Cuzick J
Drugs Today (Barc); 2005 Apr; 41(4):227-39. PubMed ID: 16034487
[TBL] [Abstract][Full Text] [Related]
40. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.
Howell A; Cuzick J; Baum M; Buzdar A; Dowsett M; Forbes JF; Hoctin-Boes G; Houghton J; Locker GY; Tobias JS;
Lancet; 2005 Jan 1-7; 365(9453):60-2. PubMed ID: 15639680
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
